Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 1,551–1,575 of 27,380 studies, newest first · page 63 of 1096.

March 2026 25

  1. 2026-03-13

    Usability and feasibility of INFORMA platform for computerized cognitive stimulation in mild cognitive impairment and early dementia: an 8-week multicenter study

    ✓ Peer-reviewed Cognitive tests and assessment Aging Clinical and Experimental Research

    Key finding: Of 219 completing participants (mean age 73.5 years), the mean SUS score was 82.0 (95% CI: 80.3-83.8), with 84% exceeding the usability threshold (SUS score > 68). +4 more findings

  2. 2026-03-13

    Progress in Machine Learning-Assisted Biosensors for Alzheimer’s Disease

    ✓ Peer-reviewed Digital health tools Biosensors

    Key finding: This disease is associated with changes in the concentration of AD biomarkers, such as microRNAs, amyloid peptides, Tau protein, and neurofilament light chains.

  3. 2026-03-13
  4. 2026-03-13

    Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease

    ✓ Peer-reviewed Treatments The Journal of Prevention of Alzheimer s Disease

    Key finding: EXT showed high cross-sectional reliability and longitudinal stability. +4 more findings

  5. 2026-03-13
  6. 2026-03-13
  7. 2026-03-13

    Telehealth among Medicare Advantage beneficiaries with and without Alzheimer's Disease and Related Dementias (ADRD), 2018–2024: from pandemic-era surge to post-pandemic decline

    ✓ Peer-reviewed Health systems and care delivery BMC Health Services Research

    Key finding: Among 421,131 MA beneficiaries, telehealth use increased sharply in Q2 2020 for both ADRD and non-ADRD groups, peaking at 33.9 and 30.6% respectively. +4 more findings

  8. 2026-03-13

    Risk Adjustment for Alzheimer Disease and Related Dementias in Medicare Advantage and Health Care Experiences

    ✓ Peer-reviewed Health systems and care delivery JAMA Network Open

    Key finding: Among 5353 MA beneficiary observations (1239 [23.1%] aged 65-74 years; 3127 [58.4%] aged ≥75 years; 1785 male [33.3%]), 1629 (30.4%) reported a diagnosis of ADRD, and 3724 (69.6%) did not report an ADRD diagnosis. +4 more findings

  9. 2026-03-13

    Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE)

    ✓ Peer-reviewed Biomarkers Alzheimer's & Dementia: Translational Research & Clinical Interventions

    Key finding: Non-elevated plasma p-tau181 results impacted the diagnosis and use of amyloid PET imaging in a memory clinic. +4 more findings

  10. 2026-03-11

    Music therapy in health care practice: promise, pitfalls, and policy implications

    ✓ Peer-reviewed Health systems and care delivery Frontiers in human neuroscience

    Key finding: This review concludes with actionable policy recommendations that are imperative to implementing music-based interventions for person-centered, holistic care and ensuring the sustainability of health care systems in the face of aging populations and rising prevalence of chronic illnesses.

  11. 2026-03-11

    Microglia protein profiles in CSF across Alzheimer’s disease clinical stages

    ✓ Peer-reviewed Inflammation and the immune system Nature Aging

    Key finding: Microglia are implicated in the progression of Alzheimer's disease (AD) pathology from its earliest stages, suggesting that cerebrospinal fluid (CSF) microglia profiling across clinical AD stages can aid in treatment development and monitoring. +2 more findings

  12. 2026-03-11

    ALS and Huntington Disease: Unraveling the Connections between TDP-43 and Huntingtin

    ✓ Peer-reviewed Brain tissue and pathology Journal of Neuroscience

    Key finding: Though their etiology and pathology are distinct, recent evidence suggests commonalities between TAR DNA-binding protein (TDP-43), which is associated with 97% of ALS cases, and huntingtin (HTT), the causative protein of HD. +2 more findings

  13. 2026-03-11

    Liver–metabolic stress, apolipoprotein E ε4, and cognition and amyloid burden: findings from the dementia platform Korea trial-ready registry

    ✓ Peer-reviewed Cognitive tests and assessment Frontiers in Aging Neuroscience

    Key finding: Routine liver–metabolic indices were associated with cognitive performance, while FIB-4 stage showed effect modification by APOE ε4 in relation to both cognition and amyloid PET SUVR. +3 more findings

  14. 2026-03-11

    Health literacy and urban–rural disparities: a cross-sectional study of access, adherence, and quality of life across the neurological spectrum

    ✓ Peer-reviewed Disparities Frontiers in Public Health

    Key finding: One-third of adults with neurological conditions in China have low health literacy, with pronounced socioeconomic and geographic disparities. +3 more findings

  15. 2026-03-11

    Anti‐amyloid antibodies in Europe: Where are we now?

    ✓ Peer-reviewed Treatments British Journal of Clinical Pharmacology

    Key finding: In the pivotal study in the overall population, the treatment showed a difference of −0.45 points between lecanemab and placebo in the adjusted mean change from baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months (the primary endpoint). +4 more findings

  16. 2026-03-11

    Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

    ✓ Peer-reviewed Tau biomarkers Nature medicine

    Key finding: Elevated p-tau levels have also been associated with cerebral deposition of Danish amyloid and prion protein amyloid. +3 more findings

  17. 2026-03-10

    Multi-site MRI analysis of morphometric differences in brain regions in the presence of hearing loss and tinnitus across the adult lifespan

    ⚠ Preprint — not yet peer-reviewed Risk factors bioRxiv

    Key finding: The impact of age and hearing loss on the brain has garnered significant attention, as both factors have been implicated in the development of cognitive impairment or dementia. +4 more findings

    Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

  18. 2026-03-10

    Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab

    ✓ Peer-reviewed Treatments The Lancet regional health. Europe

    Key finding: Recent regulatory approvals of lecanemab and donanemab in the EU mark a significant milestone. +1 more finding

  19. 2026-03-10

    Healthcare Utilization Among Older Adults With Dementia in France: A Comparative Analysis of a Dementia Village and Traditional Nursing Homes

    ✓ Peer-reviewed End-of-life care Value in Health

    Key finding: VLAHE residents had fewer hospitalizations and shorter stays (10.5 vs 15.2 days, P = .0004) than comparable NH residents, particularly for acute care. +4 more findings

  20. 2026-03-10

    LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia

    ✓ Peer-reviewed Inflammation and the immune system Redox Biology

    Key finding: Epidemiological evidence suggests that aging is associated with modifications in circulating low-density lipoprotein (LDL) and high-density lipoproteins (HDL), particularly oxidation, which further accelerates neurovascular pathology.

  21. 2026-03-10

    Fructose-2,6-bisphosphate restores TDP-43 pathology-driven genome repair deficiency in motor neuron diseases

    ✓ Peer-reviewed Brain tissue and pathology Communications Biology

    Key finding: Together, these findings reveal a critical link between metabolic dysregulation and genomic instability in TDP-43 pathology-associated motor neuron diseases, and underscore therapeutic potential of F2,6BP.

  22. 2026-03-10

    Understanding the family caregivers’ needs in late-stage dementia: a qualitative perspective to inform policy action

    ✓ Peer-reviewed Brain tissue and pathology BMC Geriatrics

    Key finding: Family caregivers had information, psychosocial, and self-care needs that were deeply intertwined and frequently coexisted at the same time. +4 more findings

  23. 2026-03-10

    TDP-43 pathology triggers neuroinflammation and cognitive impairment by inducing microglial necroptosis

    ✓ Peer-reviewed Brain tissue and pathology EMBO Molecular Medicine

    Key finding: In this study, we demonstrated that cytoplasmically mis-localized TDP-43 exacerbated neuroinflammation, induced cell death, and impaired phagocytic function in microglial cells, primarily through receptor interacting serine/threonine kinase 3 (RIPK3)-dependent necroptosis. +3 more findings

  24. 2026-03-10

    Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy

    ✓ Peer-reviewed Brain tissue and pathology Molecules

    Key finding: The cytoplasmic accumulation of TDP-43 aggregates remains a persistent pathological hallmark of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). +4 more findings

  25. 2026-03-09

    Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease

    ✓ Peer-reviewed Biomarkers Brain communications

    Key finding: This suggests that, despite the above correlations, imaging provides additional information. +1 more finding

Browse the library by subject, with the full score breakdown →